Frontier Capital Management Co. LLC Acquires 91,227 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Frontier Capital Management Co. LLC raised its holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 50.4% during the fourth quarter, Holdings Channel.com reports. The fund owned 272,088 shares of the medical device company’s stock after purchasing an additional 91,227 shares during the period. Frontier Capital Management Co. LLC’s holdings in Tandem Diabetes Care were worth $9,801,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. Franklin Resources Inc. grew its stake in shares of Tandem Diabetes Care by 95.6% during the third quarter. Franklin Resources Inc. now owns 26,785 shares of the medical device company’s stock worth $1,136,000 after purchasing an additional 13,088 shares during the period. JPMorgan Chase & Co. increased its stake in shares of Tandem Diabetes Care by 134.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 197,583 shares of the medical device company’s stock valued at $8,379,000 after acquiring an additional 113,355 shares during the last quarter. Park Avenue Securities LLC raised its position in shares of Tandem Diabetes Care by 34.5% in the 4th quarter. Park Avenue Securities LLC now owns 8,914 shares of the medical device company’s stock valued at $321,000 after acquiring an additional 2,286 shares during the period. LVW Advisors LLC boosted its stake in Tandem Diabetes Care by 13.8% during the 4th quarter. LVW Advisors LLC now owns 7,798 shares of the medical device company’s stock worth $281,000 after acquiring an additional 944 shares during the last quarter. Finally, Janney Montgomery Scott LLC grew its holdings in Tandem Diabetes Care by 17.1% during the fourth quarter. Janney Montgomery Scott LLC now owns 30,240 shares of the medical device company’s stock valued at $1,089,000 after purchasing an additional 4,412 shares during the period.

Tandem Diabetes Care Trading Up 1.1 %

TNDM stock opened at $22.98 on Friday. Tandem Diabetes Care, Inc. has a 52 week low of $15.75 and a 52 week high of $53.69. The company has a debt-to-equity ratio of 1.29, a quick ratio of 2.32 and a current ratio of 2.90. The company’s 50-day simple moving average is $18.66 and its 200 day simple moving average is $28.19. The company has a market capitalization of $1.53 billion, a PE ratio of -11.91 and a beta of 1.47.

Tandem Diabetes Care (NASDAQ:TNDM) last announced its quarterly earnings data on Wednesday, April 30th. The medical device company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.07). Tandem Diabetes Care had a negative net margin of 14.84% and a negative return on equity of 44.19%. The company had revenue of $234.42 million during the quarter, compared to analyst estimates of $220.19 million. During the same period in the prior year, the firm earned ($0.65) earnings per share. Tandem Diabetes Care’s revenue was up 22.3% on a year-over-year basis. As a group, sell-side analysts anticipate that Tandem Diabetes Care, Inc. will post -1.68 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on TNDM shares. Royal Bank of Canada reduced their price target on shares of Tandem Diabetes Care from $65.00 to $55.00 and set an “outperform” rating on the stock in a research report on Thursday, February 27th. Wells Fargo & Company decreased their target price on Tandem Diabetes Care from $22.00 to $20.00 and set an “equal weight” rating for the company in a research note on Thursday, May 1st. The Goldman Sachs Group dropped their price target on Tandem Diabetes Care from $42.00 to $24.00 and set a “neutral” rating on the stock in a research report on Monday, March 3rd. Stifel Nicolaus decreased their price objective on Tandem Diabetes Care from $60.00 to $31.00 and set a “buy” rating for the company in a research report on Thursday, May 1st. Finally, Barclays dropped their target price on shares of Tandem Diabetes Care from $60.00 to $53.00 and set an “overweight” rating on the stock in a report on Friday, February 28th. Eight investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, Tandem Diabetes Care currently has a consensus rating of “Moderate Buy” and a consensus target price of $39.81.

Insider Buying and Selling at Tandem Diabetes Care

In related news, COO Jean-Claude Kyrillos acquired 10,538 shares of the company’s stock in a transaction that occurred on Friday, March 7th. The stock was acquired at an average price of $18.12 per share, with a total value of $190,948.56. Following the purchase, the chief operating officer now directly owns 10,538 shares in the company, valued at approximately $190,948.56. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 1.90% of the company’s stock.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.